Slide 1: Conference call presentation H1 2024/25
Conference call presentation H1 2024/25 Making life easier Strive25: Sustainable Growth Leadership Dani, User, Continence Care Ostomy Care | Continence Care | Advanced Wound Care | Interventional Urology | Voice and Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Making life easier for people with intimate healthcare needs
v Our mission Making life easier for people with intimate healthcare needs Joern | Ostomy Care user
Slide 4: Q2 2024/25 financial result
NEW IMAGE Q2 2024/25 financial result Otto: add picture with Peristeen Light Update Update picture picture Organic Reported Adjusted ROIC growth EBIT margin 6% 27% * * 15% ** Update picture *before special items **after tax and before special items. Adjusted for extraordinary tax impact from the tra
Slide 5: Strategic highlights from Strive25 – Sustainable growth leadership
Strategic highlights from Strive25 – Sustainable growth leadership Growth Innovation Atos Medical Luja *, a new intermittent catheter with a Micro-hole Zone Technology • Strong performance in H1 2024/25 with 9% growth and contribution from both the • Luja for women is now available in 12 markets, wi
Slide 6: H1 organic growth of 7% with broad-based contribution, except for Interventional Urology
H1 organic growth of 7% with broad-based contribution, except for Interventional Urology which was impacted by the product recall H1 2024/25 revenue by business area H1 2024/25 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth S
Slide 7: H1 reported revenue grew 6% with ~1%-point detraction from divested operations
H1 reported revenue grew 6% with ~1%-point detraction from divested operations and a limited positive impact from currencies H1 2024/25 Revenue development (mDKK) H1 2024/25 highlights • Reported revenue increased by DKK 765 million or 6% vs. last year. • Organic growth was 7% or DKK 871 million, dr
Slide 8: Reported EBIT margin of 27% in H1, driven by higher distribution costs
Reported EBIT margin of 27%1 in H1, driven by a higher level of distribution costs, partly offset by a lower level of administration cost H1 2024/25 EBIT margin development before special items (%) H1 2024/25 highlights • Gross margin was 68%, on par with last year. • Positive impact from a favourab
Slide 9: Adjusted FCF was DKK 2,115 million in H1, with FCF-to-sales ratio of 15%
Adjusted FCF was DKK 2,115 million in H1, with a FCF-to-sales ratio of 15% FCF development1 H1 2024/25 highlights • Free cash flow for H1 2024/25 was an inflow of DKK 2,307 million, 90 93 compared to an outflow of DKK 1,326 million last year. Last year’s FCF was 84 81 81 77 impacted by the tax payme
Slide 10: FY 2024/25 financial guidance: organic growth revised to around 7%
FY 2024/25 financial guidance: organic growth revised to around 7% and EBIT margin before special items revised to 27-28% Organic revenue growth Around 7% Reported revenue growth in DKK Around 4% Reported EBIT margin* 27-28% Effective tax rate** Around 40% (Ordinary tax rate) (Around 22%) Capital ex
Slide 11: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding